Sedentary behavior is associated with insulin resistance and reduced energy expenditure, potentially blunting tirzepatide's metabolic benefits
There is also an ongoing cardiovascular outcomes trial of tirzepatide (SURPASS-CVOT) in individuals with type 2 diabetes and cardiovascular disease [91], which, if successful, will broaden the use of tirzepatide to those with manifest or increased risk for CVD, as is the case for GLP-1 receptor agonists [22]
How many times have you or someone you know struggled to keep weight off because they couldnt keep up with the high demand of being on a diet and exercising daily
Over ~3 years of follow-up, HF risk was markedly higher when prediabetes coexisted with elevated cardiac biomarkers
Thats the safest, highest-return path for women over 50 who want results without chaos
[8] [9] Second, subtherapeutic dosing may be the issue